FDA

FDA headquarters
#Duchenne muscular dystrophy #FDA #Gene therapy #Roche #Sarepta Therapeutics

FDA expands gene therapy use in Duchenne muscular dystrophy

The US Food and Drug Administration (FDA) has expanded its approval for Elevidys (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are at least four years of age. Confirming the functional benefits, the FDA granted traditional approval for ambulatory… Read More

#News #Regulatory

#FDA #Immunology / Virology & Vaccines #Moderna #mRNA #mRNA-based vaccines #Respiratory syncytial virus

US approves first mRNA vaccine since Covid-19

The US Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA… Read More

#News #Regulatory

EBV virus
#Atara Biotherapeutics #Biologics License Application (BLA) #Epstein-Barr virus #FDA #Pierre Fabre

Will this Atara Biotherapeutics drug be the first approved therapy of its kind? 

Atara Biotherapeutics has submitted a Biologics License Application (BLA) for Tabelecleucel (Tab-cel), a for treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) with the US Food and Drug Administration (FDA). There are currently no FDA approved therapies in this treatment setting.  It is indicated as monotherapy for treatment… Read More

#News #Regulatory

MRI showing glioblastoma
#Brain cancer #European Medicines Agency #FDA #Oncology #Orphan drugs

Regulatory update for malignant glioma drug

Carthera, a spin-off from Sorbonne University, has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the use of carboplatin in the treatment of malignant glioma. Carthera is using carboplatin in the first registrational trial of its SonoCloud… Read More

#News #Regulatory

#Clinical trials #FDA

FDA fast tracks Amolyt’s hypoparathyroidism therapy  

Amolyt Pharma has announced that its lead therapeutic peptide candidate, eneboparatide, has been granted fast track designation by the U.S. Food and Drug Administration (FDA).  The company’s lead therapeutic peptide candidate is currently in a Phase III clinical trial for the treatment of hypoparathyroidism.  Hypoparathyroidism… Read More

#News

Stem cells
#allogeneic cell therapies #Cell therapy #FDA #Graft vs Host Disease #Phase I trial

FDA green light for trial of allogeneic regulatory T cell therapy

The US Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for Tr1X’s TRX103 for the prevention of Graft versus Host Disease (GvHD) in patients undergoing HLA-mismatched haematopoietic stem cell transplantation (HSCT). The company plans to initiate a Phase I study of the investigational allogeneic off-the-shelf… Read More

#News #Regulatory

Antibody drug conjugate
#Accelerated assessment #Antibody drug conjugate (ADC) #AstraZeneca #Daiichi Sankyo #FDA #Oncology #Solid tumours

First tumour agnostic HER2 directed ADC gets US approval

Daiichi Sankyo and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumours. Enhertu has been granted accelerated approval to treat patients who have received prior systemic treatment and have no satisfactory alternative… Read More

#News #Regulatory

FDA headquarters
#Cancer research #Cancer therapeutics #FDA #Oncology

Study casts doubt on benefit of ‘accelerated approval’ cancer drugs

More than 40% of cancer drugs granted accelerated approval from 2013 to 2017 did not demonstrate clinical benefit in confirmatory trials, according to a study in the Journal of the American Medical Association (JAMA). The paper ‘Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval’ reviewed 46 drugs… Read More

#Editor's Choice #News #Regulatory

Cell and gene therapy
#FDA #Gene editing #Gene therapy #iECURE #In vivo #Paediatrics

FDA approves first in vivo gene insertion programme in infants

iECURE has been given the go-ahead to begin US trials of its investigational gene editing-based therapy in newborn males with neonatal onset Ornithine Transcarbamylase (OTC) deficiency. The Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for ECUR-506 makes it the first in vivo gene… Read More

#Editor's Choice #News

Dialysis machine
#Akebia #Chronic kidney disease (CKD) #FDA #Kidney disease

FDA approves new treatment option for anaemia due to kidney disease

The US Food and Drug Administration (FDA) has approved Vafseo (vadadustat) Tablets for the treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic… Read More

#News #Regulatory

#Breast cancer #Clinical trials #Covid-19 #DDW Highlights podcast #FDA #lcohol Use Disorder #Mergers and acquisitions #Psychedelics

New DDW Highlights podcast: 2 April 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In another busy week for drug discovery and development, we have seen the FDA… Read More

#News

#Alcohol Use Disorder #Breast cancer #Clinical trials #Covid-19 #FDA #Mergers and acquisitions #Psychedelics

This week in drug discovery (25-29 March) 

News round-up for 25-29 March by DDW Digital Content Editor Diana Spencer. In another busy week for drug discovery and development, we have seen the FDA approval of a monoclonal antibody for emergency use in Covid-19, the launch of trials into innovative new treatments for urea cycle disorders… Read More

#News

#Covid-19 #Covid-19 treatment #FDA #Invivyd #Monoclonal antibodies

FDA approves Covid-19 mAb for emergency use

The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to half-life extended monoclonal antibody (mAb) Pemgarda (pemivibart, or VYD222) for the pre-exposure prophylaxis (prevention) of Covid-19. It is approved in adults and adolescents (12 years of age and older weighing at least… Read More

#News

#Cardiovascular disease #FDA #Hypertension #Idorsia #Phase II trial

FDA approval represents ‘transformational progress’ in hypertension

The US Food and Drug Administration (FDA) has approved Tryvio (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. Tryvio (aprocitentan) is an endothelin receptor antagonist that inhibits the binding of endothelin… Read More

#News #Regulatory #Trending News

Gene therapy
#Cell and gene therapy #FDA #Gene therapy #Orchard Therapeutics #Paediatrics #Rare disease

First gene therapy for children with rare disease gets US sign-off

Lenmeldy (atidarsagene autotemcel) has become the first Food and Drug Administration (FDA)-approved gene therapy for the treatment of children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile metachromatic leukodystrophy (MLD). Metachromatic leukodystrophy is a debilitating, rare genetic disease affecting the brain and nervous system. It is… Read More

#News #Regulatory #Trending News

CAR-T therapy
#Blood cancer #Bristol Myers Squibb #CAR-T #Cell therapy #FDA #Leukaemia #Oncology

FDA approves first CAR-T cell therapy for relapsed CLL or SLL

The US Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It is approved in adult patients who have received at least two… Read More

#News #Regulatory #Trending News